Tag Archives: Pfizer
By Pharm Exec | Published: November 19, 2014
The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to GlobalData.
By Guest Blogger | Published: October 27, 2014
After Pfizer’s aborted acquisition of AstraZeneca, will the drug maker likely approach another company for takeover? This Applied Clinical Trials article discusses some background on Pfizer’s financial history, evaluates its R&D portfolio, and determines whether it is ready for another acquisition attempt. Read more…
By Marylyn Donahue | Published: August 21, 2014
I’ve just finished taking Pfizer’s #FOGO (Have A Fear of Getting Old?) test on getold.com. I passed with flying colors. The results assured me that I would have a hell of a time aging during these advancing years and that the last lap of my life would be a breeze. Why? I wonder. Was it […]
By Pharm Exec | Published: July 29, 2014
The launch of several drugs with “extraordinary blockbuster potential” will more than triple the acute coronary syndrome (ACS) treatment market, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.
By Tom Norton | Published: June 27, 2014
As I read the latest reports of yet another big US Rx firm, this time AbbVie, trying to pull off a “tax inversion” takeover of the Irish-based Shire, I couldn’t help but wonder, what the heck is going on here? Right now, it feels like most major US corporations, especially pharmas, are literally running away […]